Buffer-stable chitosan-polyglutamic acid hybrid nanoparticles for biomedical applications.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Drug Delivery Systems

Background:

• Chitosan (CS) nanoparticles offer promising biomedical potential but suffer from poor stability in physiological environments (pH 7.4).
• This instability limits their translation into effective therapeutic and diagnostic tools.
• Developing stable chitosan-based systems is crucial for advancing nanomedicine.

Purpose of the Study:

• To engineer and characterize buffer-stable chitosan-based hybrid nanoparticles (HNPs).
• To investigate the impact of polyglutamic acid (PGA) incorporation and crosslinking on HNP properties.
• To evaluate the in vitro cancer cell targeting efficiency of folate-conjugated HNPs.

Main Methods:

• Hybrid nanoparticles (HNPs) were synthesized by combining chitosan (CS) and polyglutamic acid (PGA).
• The molar ratio of PGA to CS and crosslinking strategies were varied to optimize HNP integrity and stability.
• Buffer stability, biodegradability, and in vitro cellular uptake of folate-conjugated HNPs were assessed.

Main Results:

• The introduction of PGA significantly enhanced the buffer stability of CS nanoparticles.
• Varying the PGA/CS ratio and crosslinking affected HNP integrity, stability, and biodegradability.
• Folate-conjugated HNPs demonstrated efficient targeted uptake in cancer cells in preliminary in vitro studies.

Conclusions:

• Chitosan-based hybrid nanoparticles (HNPs) engineered with polyglutamic acid exhibit improved stability in physiological buffer conditions.
• These stable, targeted HNPs represent a significant advancement for chitosan-based nanoparticle technology in biomedical applications.
• Further development holds promise for enhanced drug delivery and diagnostic strategies.